Valentis (VLTS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Valentis (VLTS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (59)	8/1/2001 9:53:26 AM
From: tuck	Read Replies (1) of 81

>>BURLINGAME, Calif., Aug. 1 /PRNewswire/ -- Valentis, Inc. (Nasdaq: VLTS - news) today announced that it has granted a non-exclusive license to the Company's GeneSwitch(TM) gene regulation technology to Lexicon Genetics Inc. (Nasdaq: LEXG - news) for use in functional genomics research. The non-exclusive license is for research purposes only and involves an up-front payment and annual maintenance fees. No other financial terms were disclosed. Valentis maintains all rights to clinical gene therapy applications of the GeneSwitch(TM) gene regulation technology. ``We believe the GeneSwitch technology offers significant advantages over many other currently available technologies for switching genes on and off in mammalian systems,'' stated Mark Logan, Manager of Business Development at Lexicon. ``Our evaluation of the GeneSwitch(TM) gene regulation technology indicates that it will allow Lexicon to more precisely control when and where specific genes are activated, adding another tool to our integrated technology platform for gene function and drug target discovery.'' ``The license to Lexicon Genetics represents the third commercial license of the GeneSwitch(TM) technology that we have concluded for internal commercial research efforts of pharmaceutical companies,'' stated Gregory M. McKee, Valentis' Senior Director of Business Development. ``We expect to enter into other similar GeneSwitch(TM) licenses for internal genomics research as the GeneSwitch(TM) technology has the unique ability to control gene expression and assist in the identification and characterization of the function of selected genes. We also make the GeneSwitch(TM) gene regulation system available to the academic research community through a license with Invitrogen Corp. (Nasdaq: IVGN - news).''<< snip Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next